Novel Treatment May Help Treat Hard-To-Control Hypertension, Global Trial Shows

Lorundrostat Is Specifically Designed To Lower Aldosterone Levels by Targeting and Inhibiting CYP11B2, The Enzyme That Drives ITS PRODUCTION.

The Study Demonstrated Consistnts In Blood Pressure Across A Large and Diverse Group of Patients and Represents The Largest Phase Three Trial To Date For This Class of Treatment.

Manish Saxena, MD, Clinical Co-Director of the William Harvey Heart Center at Queen Mary University of London and Hypertension Specialist From Barts Health NHS Trust and The Study’s Lead Investigator, Spoke To Medical News Today.

“Long avoilable Treatments, More than 40% OF ADULTS WITH HYPERTENSION WORLDWIDE ARE NOT REACING THES BLOOD Pressure Goal. Aldosterone Pathway plays important role in Blood Pressure Regulation, and Leads to Blood Pressure Related Complications Such as Heart Failure and Kidney Problems. In the launch-htn trial we explored the safety and effffiveness of lorundostat, which Belongs to a new class of drarugs street aldosterone synthase inhibitors that block block production of hormone aldosterone from the adrenal glands.

– Manish Saxena, MD

“The Launch-Htn Trial is the Largest Phase 3 Hypertension Study With A Novel Drug,” Saxena Explained. “We Tested Lorundostat in A Large, Diverse Patient Population Recruited Glory and Found That It Has Good Safety Profile and Lowered Blood Pressure Consistently in All of Our Patient Groups.”

How Lorundrostat Works

“Hormone aldosterone Secreted from Adrenal Glands in the body plays an important role in driving blood press. Blood Pressure. “

– Manish Saxena, MD

The Launch-Htn Trial Was A Global, Phase 3 Study That Was Randomized, Double-Blind, and Placebo-Controlled.

It included adult participants WHOSE BLOOD PRESSURE REMAINED UNCONTROLLED EVITE TAKING TWO TO Five Antihypertensive Medications.

Designed to Reflect Real-World Clinical Practice, The Trial used automated office Blood Pressure (AOBP) Measurements and Allowed participants to continue their existing treatments.

Lorundrostat, administered eleven Daily at 50 mg dose, showed meaningful and substated reductions in systolic Blood pressure – dropping by 16.9 mmhg at week 6 (at 9.1 mmhg reduction compared to placebo) and by 19 mmhg at week 12 (an 11.7 mmhg reduction versus versus versus versus versus placebo).

“The launch-htn trial demonstrated Blood pressure lowering efficient and safety of lorundrostat in a see Diverse Patient Group With Uncontrolled and Difficul To Treat Hypertension That were on background 2-5 Blood Pressure Lowering Medication Medication. Note Was consisting across key sub-goups, significant and clinically meaningful. “

– Manish Saxena, MD

Two experts, not involved in the study, Also Spoke To MNT.

Cheng-Han Chen, MD, Board Certified Interventional Cardiologist and Medical Director of the Structural Heart Program at Memorialcare Saddleback Medical Center in Laguna Hills, CA, Noted That “Aldosterone Synthase inhibitors are a New Class of Drugs Being Studied for The Treatment of HyperTension.”

“This trial Found that lorundrostat, one of these new types of drarugs, was safe and effective for patients with uncontrolled or resistant hypertension. Pressure Evite Being on Multiple Medications, ”Chen Explained.

“Many Patients Have High Blood Pressure That Are Not Under Control With Multiple Classses of Medications. By Having Another Class of Blood Pressure Medications at Our Deval, We Will Better Be Uble to reduce Rats of Hypertension in Our Population and Improve Health Outcomes.”

-Cheng-Han Cen, MD

Rigved Tadwalkar, MD, FACC, Consultative Cardiologist and Director of Digital Transformion Pacific Heart Institute in Santa Monica, Ca Told MNT that “This is a Meaningful Step Forward.”

“We Still See Far Too Many Patients With Uncontrolled Or Resistant Hypertension, Even When They’s on Three, Four, Subtimes Five Medications. The reality is that Way to Target That Mechanism Directly in A Safe, Practical Way, ”Tadwalkar Explained.

“Lorundrostat Appears to Change That. It inhibits aldosterone synthesis at the enzymatic less to 19 mmHg at 12– are significant, specially when you consider that these were already heavily treated patients.

– Rigved Tadwalkar, MD, FACC

“Since Patients Stayed on Their Background Medications, these results Feel More Clinically Relay Than More Tightly Controlled Washout Studies,” Tadwalkar Added. “It’s a Welcomo Addition to the Field, Even as we continue the limitations of existing therapies, including Newer device-based approaches like renal denervation.”

TADWALKAR SAID THAT LORUNDROSTAT HAD POTENTIAL TO MAKE A REAL DIFFERENCE IN PATENTS ‘LIVES.

“If lorundrostat becomes widely available, it could offer a new option for patients who Failure, Having Another Tool, Specially One That Targets The Underlying Hormonal Dysregulation, Could Make A Real Difference in Long-Term Outcomes, ”He Said.

SAXENA SAID THAT ONCE LORONDOSTAT BECOMES COMMERCIALLY AVAILABLE, IT COULD BECOME A Novel Treatment Option for Hypertension for Many Patients.

Tadwalkar Continued by Noting That “At the Population Level, We’re Still Facing a Hage Burden from Poorly Controlled Blood Pressure.” HE SAID UNTREATED HYPERTENSION WAS A MAJOR Contributor to Chronic Diseases and Cardiovascular Problems.

“A Drug Like This, If used properly, Could Help Narrow That Treatment Gap. It’s Certainly Not A Silver Bullet, But It’s a Step Toward More Customized, Mechanism-Specific Care. This is submissive

– Rigved Tadwalkar, MD, FACC